<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006567</article-id><article-id pub-id-type="pmc">PMC11859332</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020200</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00200</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Novel LC-MS/MS Method for the Measurement of Elexacaftor, Tezacaftor and Ivacaftor in Plasma, Dried Plasma Spot (DPS) and Whole Blood in Volumetric Absorptive Microsampling (VAMS) Devices</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2631-8610</contrib-id><name><surname>Pigliasco</surname><given-names>Federica</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00200" ref-type="aff">1</xref><xref rid="fn1-pharmaceutics-17-00200" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1132-1267</contrib-id><name><surname>Cafaro</surname><given-names>Alessia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00200" ref-type="aff">1</xref><xref rid="fn1-pharmaceutics-17-00200" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1148-427X</contrib-id><name><surname>Barco</surname><given-names>Sebastiano</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00200" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00200" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2483-5374</contrib-id><name><surname>Cresta</surname><given-names>Federico</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceutics-17-00200" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Casciaro</surname><given-names>Rosaria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceutics-17-00200" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5161-1720</contrib-id><name><surname>Pedemonte</surname><given-names>Nicoletta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-pharmaceutics-17-00200" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8460-0262</contrib-id><name><surname>Mattioli</surname><given-names>Francesca</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-pharmaceutics-17-00200" ref-type="aff">4</xref><xref rid="af5-pharmaceutics-17-00200" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1916-0963</contrib-id><name><surname>Castellani</surname><given-names>Carlo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceutics-17-00200" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Cangemi</surname><given-names>Giuliana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-pharmaceutics-17-00200" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Lanao</surname><given-names>Jos&#x000e9; Mart&#x000ed;nez</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00200"><label>1</label>Unit of Biochemistry, Pharmacology and Newborn Screening, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; <email>federicapigliasco@gaslini.org</email> (F.P.); <email>alessiacafaro@gaslini.org</email> (A.C.); <email>giulianacangemi@gaslini.org</email> (G.C.)</aff><aff id="af2-pharmaceutics-17-00200"><label>2</label>Cystic Fibrosis Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy<email>rosariacasciaro@gaslini.org</email> (R.C.); </aff><aff id="af3-pharmaceutics-17-00200"><label>3</label>UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy</aff><aff id="af4-pharmaceutics-17-00200"><label>4</label>Pharmacology &#x00026; Toxicology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 2, 16132 Genoa, Italy</aff><aff id="af5-pharmaceutics-17-00200"><label>5</label>Clinical Pharmacology Unit, EO Ospedali Galliera, Mura Delle Cappuccine, 14, 16128 Genoa, Italy</aff><author-notes><corresp id="c1-pharmaceutics-17-00200"><label>*</label>Correspondence: <email>sebastianobarco@gaslini.org</email></corresp><fn id="fn1-pharmaceutics-17-00200"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>200</elocation-id><history><date date-type="received"><day>23</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> The combination of ivacaftor, tezacaftor and elexacaftor (ETI) is approved for patients with cystic fibrosis (CF) aged two years and older and at least one F508del mutation in the CFTR gene. Variability in ETI treatment response has been repeatedly reported, and its reasons are unclear and understudied. <bold>Objectives:</bold> We present a novel liquid chromatography&#x02013;tandem mass spectrometry (LC&#x02013;MS/MS) method for the rapid and simultaneous quantification of ETI in plasma, dried plasma spots (DPS), and whole blood volumetric absorptive microsampling (VAMS). <bold>Methods:</bold> The method utilizes a rapid extraction protocol with 200 &#x003bc;L methanol after the addition of deuterated internal standards. Chromatographic separation was achieved using a reversed-phase Hypersil Gold aQ column (Thermo Fisher Scientific). The method was validated according to ICH (International Council on Harmonisation) guidelines M10 for bioanalytical method validation, demonstrating linearity in the concentration range 0.020&#x02013;12.000 &#x000b5;g/mL. It was also proved accurate and reproducible with no matrix effect. This method was applied to anonymized samples from patients undergoing ETI treatment: eight plasma and DPS and five VAMS samples were analyzed. <bold>Results:</bold> ETI concentrations measured in plasma and DPS were interchangeable, whereas ETI concentrations in VAMS were lower than in plasma, as expected for molecules with high plasma protein binding (99%). A correction factor based on the hematocrit value was used to calculate the equivalent plasma concentration from VAMS concentrations. <bold>Conclusions:</bold> This method is suitable for pharmacokinetic (PK) studies and could facilitate the centralization of samples to specialized laboratories, supporting multicenter studies.</p></abstract><kwd-group><kwd>CFTR modulators</kwd><kwd>cystic fibrosis</kwd><kwd>liquid chromatograph&#x02013;tandem mass spectrometry</kwd><kwd>microsampling</kwd><kwd>pediatric pharmacology</kwd></kwd-group><funding-group><award-group><funding-source>Italian Ministry of Health</funding-source><award-id>RC2024</award-id></award-group><funding-statement>This study has been funded by the Italian Ministry of Health, RC2024. We gratefully thank all Italian citizens who allocated the 5 &#x000d7; 1000 share of their tax payment in support of Health Research.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00200"><title>1. Introduction</title><p>Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a channel protein responsible for regulating ion transport across cell membranes [<xref rid="B1-pharmaceutics-17-00200" ref-type="bibr">1</xref>]. CFTR modulators are a novel class of drugs designed to target CFTR protein with the aim of restoring its defective function in patients affected by CF [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>]. The development and use of CFTR modulators represent a transformative therapeutic approach to the treatment of CF [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00200" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00200" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00200" ref-type="bibr">5</xref>]. Kaftrio<sup>&#x000ae;</sup> is a combination of three pharmacological agents, elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) (ETI), and is approved for patients aged two years and older with at least one F508del mutation in the <italic toggle="yes">CFTR</italic> [<xref rid="B6-pharmaceutics-17-00200" ref-type="bibr">6</xref>]. Currently, Kaftrio<sup>&#x000ae;</sup> is prescribed in a standard fixed dose for adults and adjusted by weight in children. In patients undergoing ETI treatment, variability in treatment response, including those with good adherence to treatment, has been observed [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>,<xref rid="B7-pharmaceutics-17-00200" ref-type="bibr">7</xref>]. This phenomenon may have several, possibly complementary, explanations. It has been shown that the presence of additional variants in cis with the F508del mutation may influence or even negate clinical response to ETI [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>]. Given the significant impact of CF-related pathological changes on drug absorption, distribution, metabolism, and elimination (ADME), pharmacokinetic (PK) between-subject variability (BSV) is expected [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>,<xref rid="B4-pharmaceutics-17-00200" ref-type="bibr">4</xref>]. Patients with CF undergo a heavy treatment burden, which in turn implies a high probability of drug&#x02013;drug interactions (DDIs) with ETI. This is mainly due to the metabolism of ETI in the liver, which is predominantly mediated by cytochrome P450 (CYP450) enzymes, in particular CYP3A4 and CYP3A5A [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>,<xref rid="B8-pharmaceutics-17-00200" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00200" ref-type="bibr">9</xref>]. A definitive correlation between PK parameters and ETI efficacy has not yet been established and the optimal timing for Therapeutic Drug Monitoring (TDM) sampling remains undetermined [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>,<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>]. A significant correlation between the minimum concentration (C<sub>min</sub>) measured in pre-administration ETI samples and key efficacy parameters such as sweat chloride test (Cl-), forced expiratory volume in the first second (FEV1%) and body mass index (BMI) has not been established [<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00200" ref-type="bibr">11</xref>]. Additional studies are essential to comprehensively investigate the role of PK in the variability of treatment response to ETI [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>,<xref rid="B8-pharmaceutics-17-00200" ref-type="bibr">8</xref>,<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>]. Currently, the availability of bioanalytical methods capable of simultaneously quantifying ETI in biological samples is limited to a few centers worldwide [<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>,<xref rid="B12-pharmaceutics-17-00200" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00200" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00200" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00200" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00200" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-00200" ref-type="bibr">17</xref>]. A crucial factor contributing to such scarcity is the lack of commercially available In Vitro Diagnostic Regulation (IVDR)-certified kits for ETI, and the consequent need for laboratories to develop their own in-house assays [<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>]. However, developing such methods in-house requires specialized personnel with expertise in LC-MS/MS method development, validation, optimization, and troubleshooting, which is particularly challenging and resource-intensive for many laboratories. Microsampling, an innovative sampling technique, has gained prominence as a minimally invasive method for collecting small volumes of biological fluids. When coupled with liquid chromatography&#x02013;tandem mass spectrometry (LC-MS/MS), microsampling enables precise and accurate quantification of drug concentrations in biological matrices [<xref rid="B18-pharmaceutics-17-00200" ref-type="bibr">18</xref>]. This approach presents a valuable opportunity to explore the pharmacological profile of ETI with enhanced sensitivity and reduced patient burden. Moreover, it could facilitate access to this assay for patients in centers that lack the capability to perform it. Volumetric Absorptive Microsampling (VAMS) represents an innovative technique that enables the collection of a precise volume of whole blood microsampling [<xref rid="B19-pharmaceutics-17-00200" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00200" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00200" ref-type="bibr">21</xref>]. Dried Plasma Spot (DPS) is a technique that involves spotting fixed-volume plasma microsampling onto traditional cellulose paper substrates [<xref rid="B18-pharmaceutics-17-00200" ref-type="bibr">18</xref>]. The aim of this paper is to describe the first LC-MS/MS method for the quantitation of ETI in plasma, DPS and VAMS. This advancement holds significant promise in improving our understanding of ETI PK variability. Furthermore, it enables the centralization of samples to a specialized laboratory, facilitating multicenter studies [<xref rid="B22-pharmaceutics-17-00200" ref-type="bibr">22</xref>].</p></sec><sec id="sec2-pharmaceutics-17-00200"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00200"><title>2.1. Chemicals and Reagents</title><p>Elexacaftor (ref. E201545), Tezacaftor (ref. T321510) and Ivacaftor (ref. I940600) were obtained from Toronto Research Chemicals (North York, ON, Canada). Elexacaftor d-3 (E201547), Tezacaftor d-4 (T321512) and Ivacaftor d-9 (ref. I940603) were purchased from Spectra 2000 (Rome, Italy). LC&#x02013;MS/MS-grade formic acid (ref. 607001000), LC&#x02013;MS/MS-grade acetonitrile (ref. 1.00029) and dimethyl sulfoxide (DMSO) were obtained from Sigma (Milan, Italy); LC&#x02013;MS/MS-grade methanol (ref. 414942) was obtained from Carlo Erba reagents (Cornaredo, Milan, Italy). All reagents have 98% purity. All solutions were prepared using HPLC-grade water from a Milli-Q Plus water purification system. HPLC mobile phases were filtered through Millipore membrane filters [0.45 &#x000b5;m] (Millipore, Vimodrone MI, Italy).</p></sec><sec id="sec2dot2-pharmaceutics-17-00200"><title>2.2. Calibration Curve, Quality Control, Stock and Working Solutions Preparation</title><p>ELX, TEZ and IVA were dissolved in DMSO to prepare stock solutions at concentrations of 2.600 mg/mL, 1.600 mg/mL, and 2.500 mg/mL, respectively. Stock solution of internal standards (IS) of Tezacaftor d-9 (TEX d-9) (0.5 mg/mL), Elexacaftor d-3 (ELX d-3) (0.500 mg/mL) and Ivacaftor d-9 (IVA d-9) (1 mg/mL) were prepared by dissolving any substance in DMSO. A working solution of ELX, TEZ and IVA (100 &#x000b5;g/mL) was obtained by diluting the respective stock solutions in methanol. An IS mixture working solution containing ELX d-3, TEX d-9 and IVA d-5 was obtained by diluting each stock solution to achieve a final concentration of 0.500 &#x000b5;g/mL for each IS. Calibrators and Quality Controls (QCs) were generated by diluting the working solutions in blank plasma collected from healthy adult volunteers. An 8-point calibration curve for ELX, TEZ and IVA was established with concentrations ranging from 0.020 to 12.000 &#x000b5;g/mL, specifically: 0.020 (lower limit of quantification, LLOQ), 0.050, 0.120, 0.30, 0.770, 1.920, 4.800 and 12.000 &#x000b5;g/mL. Additionally, three QCs were prepared at concentrations of 0.060 &#x000b5;g/mL (QC low), 0.400 &#x000b5;g/mL (QC medium) and 10.000 &#x000b5;g/mL (QC high).</p></sec><sec id="sec2dot3-pharmaceutics-17-00200"><title>2.3. Human Samples</title><p>We evaluated the applicability of the described bioanalytical method based on LC-MS/MS for the measurement of ETI in plasma, DPS and whole-blood VAMS. The method followed the ethical standards of the Institutional and National Research Committee and the 1975 Helsinki Declaration, revised in 2013. Written informed consent for collecting residual samples and anonymized clinical data was obtained from all patients or their legal representatives according to the privacy policy of the IRCCS Istituto Giannina Gaslini, Genoa, Italy. In accordance with international guidelines on bioanalytical method validation, we analyzed samples from eight patients treated with Kaftrio<sup>&#x000ae;</sup> and followed them at IRCC Istituto Giannina Gaslini. Leftover whole blood samples for routine analysis with ethylenediaminetetraacetic acid (EDTA) as an anticoagulant were centrifuged at 20,000&#x000d7; <italic toggle="yes">g</italic> for 5 min at 4 &#x000b0;C to obtain plasma. Plasma and DPS samples were obtained from all of them while VAMS were obtained from five of them. All samples were obtained before the ETI morning administration.</p></sec><sec id="sec2dot4-pharmaceutics-17-00200"><title>2.4. Sample Pre-Treatment</title><sec id="sec2dot4dot1-pharmaceutics-17-00200"><title>2.4.1. Extraction from Plasma</title><p>A 50 &#x003bc;L aliquot of plasma sample (calibrators, QC or patient&#x02019;s) was mixed with 200 &#x003bc;L aliquot of methanol (MeOH) following the addition of 5 &#x000b5;L of IS mixture working solution (0.5 &#x003bc;g/mL). After thorough vortexing, the samples were centrifuged at 20,000&#x000d7; <italic toggle="yes">g</italic> for 5 min at 4 &#x000b0;C and the supernatants were then transferred to autosampler glass vials for injection into the LC-MS/MS system.</p></sec><sec id="sec2dot4dot2-pharmaceutics-17-00200"><title>2.4.2. Extraction from DPS</title><p>Calibration standards, QCs and patient samples (20 &#x003bc;L each) were carefully applied to Ahlstrom 226 filter paper using a calibrated pipette and allowed to air dry at room temperature (25 &#x000b1; 2 &#x000b0;C) for 1 h. Each DPS was then punched to obtain eight disks, each with a diameter of 3.2 mm (approximately 3.3&#x02013;3.4 &#x003bc;L of plasma). These disks were placed into 1.5 mL Eppendorf tubes and extracted with 200 &#x003bc;L of methanol, with the addition of 5 &#x003bc;L of IS mixture working solution (0.500 &#x003bc;g/mL). After a 10 min incubation at 37 &#x000b1; 1 &#x000b0;C, the samples were centrifuged at 20,000&#x000d7; <italic toggle="yes">g</italic> for 5 min at 4 &#x000b0;C. The supernatants were then collected into autosampler glass vials for injection into the LC-MS/MS system.</p></sec><sec id="sec2dot4dot3-pharmaceutics-17-00200"><title>2.4.3. Preparation and Extraction from VAMS</title><p>VAMS (MITRA<sup>&#x000ae;</sup>, Neoteryx, Torrance, CA, USA) samples were prepared using the 30 &#x000b5;L device model following the manufacturer&#x02019;s instructions. The upper part of the tip was carefully dipped into a volume of blood, ensuring that the tip was not fully immersed to avoid overfilling. Once the tip turned completely red, it was held in place for an additional 2 s. The devices were air-dried for 1 h at room temperature and protected from light. VAMS tips were placed into 1.5 mL Eppendorf tubes and extracted with 200 &#x003bc;L of methanol, with the addition of 5 &#x003bc;L of IS mixture working solution (0.500 &#x003bc;g/mL). After a 10 min incubation at 37 &#x000b1; 1 &#x000b0;C, the samples were centrifuged at 20,000&#x000d7; <italic toggle="yes">g</italic> for 5 min at 4 &#x000b0;C. The supernatants were then transferred to autosampler glass vials for LC-MS/MS analysis.</p></sec></sec><sec id="sec2dot5-pharmaceutics-17-00200"><title>2.5. LC-MS/MS Conditions</title><sec id="sec2dot5dot1-pharmaceutics-17-00200"><title>2.5.1. Chromatographic Separation</title><p>Chromatography analyses were performed using Ultimate 3000 UHPLC Dual-Gradient Pumps (Thermo Fisher Scientific, Milan, Italy), a Hypersil Gold aQ column (2.1 mm &#x000d7; 50 mm, i.d. 1.9 &#x000b5;m, Thermo Fisher Scientific, Milan, Italy) maintained at 50 &#x000b0;C. Water with 0.1% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> formic acid was used as eluent A and acetonitrile (ACN) with 0.1% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> formic acid as eluent B, with a flow rate set at 600 &#x000b5;L/min. The gradient program began at 10% eluent B and ramped up to 100% eluent B over 0.7 min, which was held for 1.05 min. The column was then re-equilibrated with 10% eluent B for 1.75 min, resulting in a total run time of 3.5 min. The injection volume was 5 &#x000b5;L.</p></sec><sec id="sec2dot5dot2-pharmaceutics-17-00200"><title>2.5.2. Mass Spectrometric Acquisition</title><p>The system (TSQ Quantiva MS/MS) was set to operate in scheduled multiple reaction monitoring (MRM) mode. The vaporizer and capillary temperatures were maintained at 350 &#x000b0;C. Nitrogen was used as both the nebulizer and auxiliary gases, set to 45 and 10 arbitrary units, respectively. Argon served as the collision gas, with a pressure of 1.5 mTorr.</p><p>The specific transitions, detected using multiple reaction monitoring (MRM) were: 598.3&#x02192;422.2 for ELX, 601.4&#x02192;422.2 for ELX d-3, 521.3&#x02192;387.1 for TEZ, 525.3&#x02192;391.1 for TEZ d-4, 393.2&#x02192; 319.1 for IVA and 402.2&#x02192; 328.1 for IVA d-9,</p></sec></sec><sec id="sec2dot6-pharmaceutics-17-00200"><title>2.6. Method Validation</title><p>The method has been validated according to the ICH guidelines M10 on bioanalytical methods validation [<xref rid="B23-pharmaceutics-17-00200" ref-type="bibr">23</xref>].</p><sec id="sec2dot6dot1-pharmaceutics-17-00200"><title>2.6.1. Selectivity and Specificity</title><p>For selectivity and specificity assessment, plasma samples from ten healthy volunteers who were not taking drugs and from patients on Kaftrio<sup>&#x000ae;</sup> therapy were analyzed. For the analysis, an LLOQ (lower limit of quantitation) sample, a QC high sample and a sample spiked with an internal standard (IS) were prepared using human blank plasma. Each batch of samples was processed and analyzed using the same method. The criterion for acceptable performance was that the signal for each analyte should be less than 20% of the LLOQ, indicating the absence of interfering components.</p></sec><sec id="sec2dot6dot2-pharmaceutics-17-00200"><title>2.6.2. Carry-Over</title><p>Carry-over was assessed by analyzing triplicate blank samples after the injection of the highest calibration standard into the LC-MS/MS. The carry-over was considered negligible for a signal in the blank sample within 20% LLOQ and 5% IS.</p></sec><sec id="sec2dot6dot3-pharmaceutics-17-00200"><title>2.6.3. Matrix Effect and Extraction Recovery</title><p>Matrix effect and extraction recovery were evaluated by analyzing 6 lots of blank matrix samples from healthy donors. Matrix effect was assessed through a &#x0201c;T&#x0201d; fitting, the output of the chromatographic column was connected with a syringe, with a solution of ETI at 5 &#x000b5;g/mL and connected to the source. A blank matrix sample (DPS and VAMS) was injected into the column, and the solution was infused simultaneously through the syringe. The described procedure allowed us to verify if the ionization of ETI was affected by interferents present in the matrix.</p><p>Extraction recovery for ETI and IS was assessed by analyzing QC low and QC high in triplicate for each matrix (plasma, DPS and VAMS) and comparing the peak areas of all assayed analytes before extraction with the peak areas of ETI after extraction.</p></sec><sec id="sec2dot6dot4-pharmaceutics-17-00200"><title>2.6.4. Linearity</title><p>Linearity was assessed by analyzing three calibration curves on different days. The ratio of the analyte peak area to the IS was plotted against the analyte concentration for each calibration standard, with the data weighted using a 1/x factor. The calibration curves were validated in the concentration range of 0.020&#x02013;12.000 m&#x000b5;g/mL for all analytes. The acceptance criterion for the recalculated concentrations of the calibration standards was within 15% of the theoretical value, with the exception of LLOQ, which had a tolerance of 20%.</p></sec><sec id="sec2dot6dot5-pharmaceutics-17-00200"><title>2.6.5. Precision, Accuracy and LLOQ</title><p>Intra-day precision and accuracy were assessed by analyzing the LLOQ and QC samples in quintuplicate within a single analytical run. Inter-day accuracy and precision were evaluated by testing the LLOQ and QC samples in triplicate across three separate analytical runs. Accuracy was determined as the percentage difference from the nominal value, while precision was expressed as the coefficient of variation (CV%). Accuracy was considered acceptable within 85&#x02013;115% for QCs and within 80&#x02013;120% for the LLOQ. Precision was deemed acceptable if the CV% was within &#x000b1;15% for QCs and &#x000b1;20% for the LLOQ. Additionally, the signal-to-noise ratio for the LLOQ was required to be greater than 5.</p></sec><sec id="sec2dot6dot6-pharmaceutics-17-00200"><title>2.6.6. Stability</title><p>The stability of ELX, TEZ and IVA in plasma, DPS and VAMS was assessed by analyzing three replicates of QC low and QC high after storage at +4 &#x000b0;C and room temperature (RT) at the following times: 3 and 7 days. The stability of stock and working solution was tested after storage at &#x02212;20 &#x000b0;C for 4 weeks. Stability was considered acceptable if the percentage difference between the concentration measured at each sampling point and the initial concentration was within &#x000b1;15%.</p></sec></sec><sec id="sec2dot7-pharmaceutics-17-00200"><title>2.7. Statistical Analyses</title><p>Descriptive statistics were compiled for the entire cohort, with data presented as the mean and standard deviation for continuous variables. For categorical variables, absolute and relative frequencies were reported, while median values and ranges were calculated and documented as well. Statistical analyses were conducted using MedCalc software, ver 22.021 (MedCalc Software Ltd., Ostend, Belgium).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00200"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00200"><title>3.1. Method Development</title><p>The presented method for the simultaneous quantification of ETI in different matrices (DPS and VAMS) was developed on an Ultimate 3000 UHPLC Dual-Gradient Pumps coupled to a TSQ Quantiva MS/MS in positive ionization mode. The MRM acquisition mode was used in order to set up an accurate and selective quantification method. Transitions were chosen by direct injection of pure compounds into the mass spectrometer. CID-induced fragmentation of protonated ions for all analytes produced two major daughter ions, the quantifier ion and the qualifier ion. The use of the Hypersil Gold aQ column allowed us to achieve optimal chromatographic resolution, thereby reducing interferences. The chromatograms in <xref rid="app1-pharmaceutics-17-00200" ref-type="app">Supplementary Figure S1</xref> demonstrate the excellent resolution and intensity provided by the chosen chromatographic column. The total run time was 3.5 min, with retention times of 1.79 min for ELX, 1.61 min for TEZ, and 1.71 min for IVA.</p></sec><sec id="sec3dot2-pharmaceutics-17-00200"><title>3.2. Method Validation</title><p>The method was validated following the ICH guidelines M10 [<xref rid="B23-pharmaceutics-17-00200" ref-type="bibr">23</xref>] and the results obtained showed excellent precision and accuracy for the quantification of ETI in plasma, DPS and VAMS. No interfering peaks were detected under the specified LC-MS/MS conditions, and carry-over was found to be negligible. ER tests gave results within the acceptable ranges (&#x0003c;15% for all the analytes tested). Matrix effect evaluation revealed no significant deviations from the signal (both ion suppression and/or enhancement) at the retention times of ETI.</p><p>The lower limit of quantification (LLOQ) resulted in 0.020 &#x000b5;g/mL. The calibration curves for all analytes were built using quadratic equations and the ratio of the analyte peak area to the IS (analyte/IS) was plotted by using a 1/x weighting factor. The corresponding concentration was achieved across the entire concentration range, with an R<sup>2</sup> value of 0.99. The back-calculated concentrations for all analytes were within &#x000b1;15% of the nominal values. The mean calibration curve statistics and R<sup>2</sup> for IVA, TEZ and ELX, in plasma, DPS and VAMS have been summarized in <xref rid="app1-pharmaceutics-17-00200" ref-type="app">Supplementary Table S1</xref>. <xref rid="app1-pharmaceutics-17-00200" ref-type="app">Supplementary Figure S2</xref> shows the mean calibration curves for ETI in plasma (panel A), DPS (panel B) and VAMS (panel C). Results of intra- and inter-day precision and accuracy were acceptable for ETI in plasma, DPS and VAMS (<xref rid="pharmaceutics-17-00200-t001" ref-type="table">Table 1</xref>). The stability results for plasma, DPS, and VAMS samples containing ETI are summarized in <xref rid="pharmaceutics-17-00200-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec3dot3-pharmaceutics-17-00200"><title>3.3. Analyses of Clinical Samples</title><p>A total of 21 samples derived from eight patients were analyzed. Patients were males (n = 5) and females (n = 3) with a median age of 27 years (range, 14&#x02013;61 years). Eight plasma and DPS and five VAMS samples were analyzed.</p><p><xref rid="pharmaceutics-17-00200-t003" ref-type="table">Table 3</xref> shows the concentrations obtained for plasma, DPS and VAMS. According to D&#x02019;Urso and colleagues [<xref rid="B24-pharmaceutics-17-00200" ref-type="bibr">24</xref>], the blood/plasma ratio (R) for VAMS was determined by dividing the drug concentration in VAMS by the plasma concentration. The mean R values were found to be less than 1, specifically 0.59 &#x000b1; 0.07 for TEZ, 0.64 &#x000b1; 0.11 for IVA, and 0.63 &#x000b1; 0.09 for ELX, which is in line with the high plasma protein binding of ETI (99%). Since whole blood was used for determining ETI on VAMS, it was necessary to consider the hematocrit value (HCT) to obtain a correction factor, which allowed for the calculation of the corrected VAMS concentration values using the following formulas:<disp-formula id="FD1-pharmaceutics-17-00200"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi>V</mml:mi><mml:mi>A</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi>V</mml:mi><mml:mi>A</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>100</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>H</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The percentage difference between plasma and DPS ETI concentrations, as well as between plasma and VAMS ETI concentrations, was calculated for each sample, with all results falling within &#x000b1;20% (<xref rid="pharmaceutics-17-00200-t003" ref-type="table">Table 3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00200"><title>4. Discussion</title><p>TDM plays a pivotal role in optimizing drug efficacy and minimizing adverse drug reactions (ADRs), particularly in conditions like CF where physiological or pathological factors can significantly impact PKs [<xref rid="B4-pharmaceutics-17-00200" ref-type="bibr">4</xref>]. Reliable methods for the quantification of ETI in plasma are a mandatory requirement to conduct PK studies. The LC-MS/MS technique is widely recognized as the gold standard for accurately quantifying drugs in biological fluids [<xref rid="B22-pharmaceutics-17-00200" ref-type="bibr">22</xref>,<xref rid="B25-pharmaceutics-17-00200" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00200" ref-type="bibr">26</xref>]. A TDM protocol for ETI could serve as a valuable tool in clinical practice to identify inadequate clinical responses resulting from insufficient drug exposure or suboptimal adherence to treatment. The timing of blood collection is critical in TDM to yield clinically relevant information [<xref rid="B3-pharmaceutics-17-00200" ref-type="bibr">3</xref>], as improper timing can lead to inappropriate drug dosage adjustments, either resulting in subtherapeutic or toxic drug levels, compromising both patient safety and the effectiveness of the therapy. For ETI, the optimal time points for sample collection, such as maximum concentration (Cmax), Cmin, or area under the plasma concentration-time curve (AUC), remain undefined [<xref rid="B2-pharmaceutics-17-00200" ref-type="bibr">2</xref>]. A prior study conducted by our group failed to demonstrate any significant correlation between ETI Cmin levels and the clinical response to treatment as measured by Cl-, FEV1% and BMI [<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>]. This suggests that pre-dose blood collection might not be the most suitable time for TDM sample collection. A strong positive linear correlation between Ctrough and AUC<sub>0&#x02013;24</sub> for each of the three components of ETI has been demonstrated [<xref rid="B27-pharmaceutics-17-00200" ref-type="bibr">27</xref>], suggesting that AUC may not be the optimal pharmacokinetic parameter for ETI TDM. However, this study was conducted with only seven adult patients, and larger, more comprehensive studies are needed. Notably, a statistically significant negative association was observed between BMI and Cmax values for TEZ in patients receiving the full dose of ETI, as well as between FEV1 and ELX levels in patients on a reduced dose [<xref rid="B11-pharmaceutics-17-00200" ref-type="bibr">11</xref>]. These findings suggest a potential role for C<sub>max</sub> in TDM. Additional PK studies are needed to elucidate ETI drug exposure&#x02013;clinical response and safety relationships, which remain limited. Given the necessity for multicentric PK studies to clarify any role of TDM in assessing treatment response variability, and the need to establish reference ranges and considering that monitoring ETI exposure is currently restricted to only a few centers worldwide, this study presents, for the first time, a method for the simultaneous measurement of all three components of ETI in plasma, DPS and whole blood using VAMS.</p><p>Various methods have been published for the quantification of ETI from plasma samples [<xref rid="B10-pharmaceutics-17-00200" ref-type="bibr">10</xref>,<xref rid="B12-pharmaceutics-17-00200" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00200" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00200" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00200" ref-type="bibr">15</xref>] and a method from dried blood spots (DBSs) [<xref rid="B16-pharmaceutics-17-00200" ref-type="bibr">16</xref>]. Microsampling techniques, including DBS, DPS and VAMS, offer distinct advantages over conventional blood collection. The minimal volume required (only a few microliters) is particularly beneficial for pediatric and neonatal populations, where obtaining large volumes of blood is challenging and risky. While both VAMS and DBS offer benefits as microsampling techniques, VAMS provides additional advantages. In fact, VAMS is an advanced volumetric sampling technique that facilitates the collection of accurate whole blood volumes [<xref rid="B19-pharmaceutics-17-00200" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00200" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00200" ref-type="bibr">21</xref>], while in DBS, the variability in blood spot size can lead to inconsistent sample volumes and thus inaccurate drug measurement. VAMS devices are designed to absorb a precise and fixed amount of blood, improving the reproducibility of results. The collection of an accurate blood volume allows us to avoid the Hct Effect: DBS analysis is influenced by the Hct level of the blood, affecting the distribution and drying pattern of the sample. VAMS minimizes this issue, leading to more reliable and consistent analyte quantification. DPS involves spotting a fixed plasma volume onto cellulose substrates, which is particularly advantageous for multicenter studies requiring external laboratory processing, given its superior stability compared to fresh plasma [<xref rid="B18-pharmaceutics-17-00200" ref-type="bibr">18</xref>]. However, it is important to note that compared to blood collection on VAMS, DPS entails a conventional venipuncture procedure conducted by qualified healthcare personnel, followed by laboratory processing of the whole blood sample through centrifugation [<xref rid="B18-pharmaceutics-17-00200" ref-type="bibr">18</xref>].</p><p>In the present study, to enhance method reliability and accuracy, deuterated IS is utilized for each analyte. A thorough stability study confirmed that ETI is stable in plasma, DPS and VAMS for up to one week (<xref rid="pharmaceutics-17-00200-t002" ref-type="table">Table 2</xref>) facilitating convenient sample shipment. The ETI concentrations measured in plasma and DPS were found to be interchangeable, while the ETI concentrations in VAMS were lower than those in plasma. This finding aligns with expectations for drugs with a very high plasma protein binding (99%) and is consistent with Vonk et al. [<xref rid="B16-pharmaceutics-17-00200" ref-type="bibr">16</xref>], who reported lower ETI concentrations in DBS compared to plasma. A correction factor based on the hematocrit value allowed us to calculate the equivalent plasma concentration. Cross-validation across the three matrices was not feasible, as ICH guidelines M10 specify a requirement for either a Bland&#x02013;Altman test or Deming regression, both of which necessitate a minimum of 30 samples. Further studies are required to validate this VAMS-based method using capillary blood obtained from real patient finger or heel pricks and to conduct a cross-validation statistical analysis between the different matrices with an adequate sample size.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-00200"><title>5. Conclusions</title><p>In this paper, we show a novel LC-MS/MS method for quantifying ETI in plasma, DPS and VAMS. This method, validated in accordance with ICH guidelines M10, is suitable for TDM and PK multicentric studies. Its application could significantly contribute to the management of ETI therapy in CF patients.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00200"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020200/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020200/s1</uri>. Figure S1: Chromatograms obtained from the analysis of ETI in plasma (panel A), DPS (panel B) and VAMS (panel C). RT is retention time. Figure S2. Mean calibration curves (8 point calibration curve) of IVA, TEZ and ELX ranging from 0.02 to 12.00 mg/L in plasma (panel A), in DPS (panel B) and in VAMS (panel C). Table S1: The equation of mean calibration curve statistics and R<sup>2</sup> for IVA, TEZ and ELX, in plasma, DPS and VAMS.</p><supplementary-material id="pharmaceutics-17-00200-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00200-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, C.C. and G.C.; Methodology, F.P., A.C. and S.B.; Validation, F.P. and S.B.; Resources, C.C.; Data curation, F.P., A.C. and S.B.; Writing&#x02014;original draft, F.P., A.C. and G.C.; Writing&#x02014;review &#x00026; editing, A.C., S.B., F.C., R.C., N.P., F.M., C.C. and G.C.; Visualization, F.C., R.C., N.P. and G.C.; Supervision, F.C., R.C., N.P., F.M., C.C. and G.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was approved by IRCCS Istituto Giannina Gaslini&#x02019;s Internal Review Board (0037117/22-01/12/2022).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-pharmaceutics-17-00200" ref-type="app">Supplementary Materials</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00200"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castellani</surname><given-names>C.</given-names></name>
<name><surname>Assael</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Cystic fibrosis: A clinical view</article-title><source>Cell. Mol. Life Sci.</source><year>2017</year><volume>74</volume><fpage>129</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2393-9</pub-id><pub-id pub-id-type="pmid">27709245</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00200"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choong</surname><given-names>E.</given-names></name>
<name><surname>Sauty</surname><given-names>A.</given-names></name>
<name><surname>Koutsokera</surname><given-names>A.</given-names></name>
<name><surname>Blanchon</surname><given-names>S.</given-names></name>
<name><surname>Andr&#x000e9;</surname><given-names>P.</given-names></name>
<name><surname>Decosterd</surname><given-names>L.</given-names></name>
</person-group><article-title>Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1674</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14081674</pub-id><pub-id pub-id-type="pmid">36015300</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00200"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elborn</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Cystic fibrosis</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>2519</fpage><lpage>2531</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00576-6</pub-id><pub-id pub-id-type="pmid">27140670</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00200"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castagnola</surname><given-names>E.</given-names></name>
<name><surname>Cangemi</surname><given-names>G.</given-names></name>
<name><surname>Mesini</surname><given-names>A.</given-names></name>
<name><surname>Castellani</surname><given-names>C.</given-names></name>
<name><surname>Martelli</surname><given-names>A.</given-names></name>
<name><surname>Cattaneo</surname><given-names>D.</given-names></name>
<name><surname>Mattioli</surname><given-names>F.</given-names></name>
</person-group><article-title>Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: A narrative review</article-title><source>Int. J. Antimicrob. Agents</source><year>2021</year><volume>58</volume><fpage>106381</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106381</pub-id><pub-id pub-id-type="pmid">34157401</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00200"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shteinberg</surname><given-names>M.</given-names></name>
<name><surname>Haq</surname><given-names>I.J.</given-names></name>
<name><surname>Polineni</surname><given-names>D.</given-names></name>
<name><surname>Davies</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Cystic fibrosis</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2195</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32542-3</pub-id><pub-id pub-id-type="pmid">34090606</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00200"><label>6.</label><element-citation publication-type="webpage"><article-title>Kaftrio|European Medicines Agency, n.d</article-title><comment>Available online: <ext-link xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-01">(accessed on 1 September 2024)</date-in-citation></element-citation></ref><ref id="B7-pharmaceutics-17-00200"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sondo</surname><given-names>E.</given-names></name>
<name><surname>Cresta</surname><given-names>F.</given-names></name>
<name><surname>Pastorino</surname><given-names>C.</given-names></name>
<name><surname>Tomati</surname><given-names>V.</given-names></name>
<name><surname>Capurro</surname><given-names>V.</given-names></name>
<name><surname>Pesce</surname><given-names>E.</given-names></name>
<name><surname>Lena</surname><given-names>M.</given-names></name>
<name><surname>Iacomino</surname><given-names>M.</given-names></name>
<name><surname>Baffico</surname><given-names>A.M.</given-names></name>
<name><surname>Coviello</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>3175</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23063175</pub-id><pub-id pub-id-type="pmid">35328596</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00200"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bentley</surname><given-names>S.</given-names></name>
<name><surname>Cheong</surname><given-names>J.</given-names></name>
<name><surname>Gudka</surname><given-names>N.</given-names></name>
<name><surname>Makhecha</surname><given-names>S.</given-names></name>
<name><surname>Hadjisymeou-Andreou</surname><given-names>S.</given-names></name>
<name><surname>Standing</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: Recent advances and future outlooks</article-title><source>Expert. Rev. Clin. Pharmacol.</source><year>2023</year><volume>16</volume><fpage>715</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1080/17512433.2023.2238597</pub-id><pub-id pub-id-type="pmid">37470695</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00200"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pigliasco</surname><given-names>F.</given-names></name>
<name><surname>Barco</surname><given-names>S.</given-names></name>
<name><surname>Pedemonte</surname><given-names>N.</given-names></name>
<name><surname>Cresta</surname><given-names>F.</given-names></name>
<name><surname>Casciaro</surname><given-names>R.</given-names></name>
<name><surname>Castellani</surname><given-names>C.</given-names></name>
<name><surname>Cafaro</surname><given-names>A.</given-names></name>
</person-group><article-title>Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica</article-title><source>Rev. Rassegne Biochim. Clin.</source><year>2023</year><volume>47</volume><elocation-id>127</elocation-id><pub-id pub-id-type="doi">10.19186/BC_2023.027</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-00200"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pigliasco</surname><given-names>F.</given-names></name>
<name><surname>Cafaro</surname><given-names>A.</given-names></name>
<name><surname>Stella</surname><given-names>M.</given-names></name>
<name><surname>Baiardi</surname><given-names>G.</given-names></name>
<name><surname>Barco</surname><given-names>S.</given-names></name>
<name><surname>Pedemonte</surname><given-names>N.</given-names></name>
<name><surname>D&#x02019;orsi</surname><given-names>C.</given-names></name>
<name><surname>Cresta</surname><given-names>F.</given-names></name>
<name><surname>Casciaro</surname><given-names>R.</given-names></name>
<name><surname>Castellani</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients&#x02019; Plasma by a Novel LC-MS/MS Method</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><elocation-id>628</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines11020628</pub-id><pub-id pub-id-type="pmid">36831163</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00200"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naehrig</surname><given-names>S.</given-names></name>
<name><surname>Shad</surname><given-names>C.</given-names></name>
<name><surname>Breuling</surname><given-names>M.</given-names></name>
<name><surname>Goetschke</surname><given-names>M.</given-names></name>
<name><surname>Habler</surname><given-names>K.</given-names></name>
<name><surname>Sieber</surname><given-names>S.</given-names></name>
<name><surname>Kastenberger</surname><given-names>J.</given-names></name>
<name><surname>Kunzelmann</surname><given-names>A.K.</given-names></name>
<name><surname>Sommerburg</surname><given-names>O.</given-names></name>
<name><surname>Liebchen</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis</article-title><source>J. Pers. Med.</source><year>2024</year><volume>14</volume><elocation-id>1065</elocation-id><pub-id pub-id-type="doi">10.3390/jpm14101065</pub-id><pub-id pub-id-type="pmid">39452571</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00200"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>HablHabler</surname><given-names>K.</given-names></name>
<name><surname>Kalla</surname><given-names>A.-S.</given-names></name>
<name><surname>Rychlik</surname><given-names>M.</given-names></name>
<name><surname>Bruegel</surname><given-names>M.</given-names></name>
<name><surname>Teupser</surname><given-names>D.</given-names></name>
<name><surname>N&#x000e4;hrig</surname><given-names>S.</given-names></name>
<name><surname>Vogeser</surname><given-names>M.</given-names></name>
<name><surname>Paal</surname><given-names>M.</given-names></name>
</person-group><article-title>Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum</article-title><source>Clin. Chem. Lab. Med.</source><year>2022</year><volume>60</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1515/cclm-2021-0724</pub-id><pub-id pub-id-type="pmid">34668357</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00200"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vonk</surname><given-names>S.E.M.</given-names></name>
<name><surname>van der Meer-Vos</surname><given-names>M.</given-names></name>
<name><surname>Bos</surname><given-names>L.D.J.</given-names></name>
<name><surname>Neerincx</surname><given-names>A.H.</given-names></name>
<name><surname>Majoor</surname><given-names>C.J.</given-names></name>
<name><surname>der Zee</surname><given-names>A.-H.M.-V.</given-names></name>
<name><surname>Math&#x000f4;t</surname><given-names>R.A.A.</given-names></name>
<name><surname>Kemper</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography with Tandem Mass Spectrometry and Its Clinical Applicability</article-title><source>Ther. Drug Monit.</source><year>2021</year><volume>43</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000829</pub-id><pub-id pub-id-type="pmid">33165217</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00200"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reyes-Ortega</surname><given-names>F.</given-names></name>
<name><surname>Qiu</surname><given-names>F.</given-names></name>
<name><surname>Schneider-Futschik</surname><given-names>E.K.</given-names></name>
</person-group><article-title>Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method</article-title><source>ACS Pharmacol. Transl. Sci.</source><year>2020</year><volume>3</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.0c00103</pub-id><pub-id pub-id-type="pmid">33073196</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00200"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>E.K.</given-names></name>
<name><surname>Reyes-Ortega</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Velkov</surname><given-names>T.</given-names></name>
</person-group><article-title>Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients</article-title><source>J. Vis. Exp.</source><year>2017</year><volume>2017</volume><fpage>56084</fpage><pub-id pub-id-type="doi">10.3791/56084-v</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-00200"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vonk</surname><given-names>S.E.M.</given-names></name>
<name><surname>van der Meer-Vos</surname><given-names>M.</given-names></name>
<name><surname>Kos</surname><given-names>R.</given-names></name>
<name><surname>Neerincx</surname><given-names>A.H.</given-names></name>
<name><surname>Terheggen-Lagro</surname><given-names>S.W.J.</given-names></name>
<name><surname>Altenburg</surname><given-names>J.</given-names></name>
<name><surname>der Zee</surname><given-names>A.H.M.-V.</given-names></name>
<name><surname>Math&#x000f4;t</surname><given-names>R.A.A.</given-names></name>
<name><surname>Kemper</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS</article-title><source>Ther. Drug Monit.</source><year>2024</year><volume>46</volume><fpage>804</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000001231</pub-id><pub-id pub-id-type="pmid">38935410</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00200"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Rouillon</surname><given-names>S.</given-names></name>
<name><surname>Khemakhem</surname><given-names>M.</given-names></name>
<name><surname>Balakirouchenane</surname><given-names>D.</given-names></name>
<name><surname>Lui</surname><given-names>G.</given-names></name>
<name><surname>Abdalla</surname><given-names>S.</given-names></name>
<name><surname>Sanoufi</surname><given-names>M.R.</given-names></name>
<name><surname>Sauvaitre</surname><given-names>L.</given-names></name>
<name><surname>Thebault</surname><given-names>L.</given-names></name>
<name><surname>Hirt</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>A rapid LC-MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma</article-title><source>J. Pharm. Biomed. Anal.</source><year>2024</year><volume>248</volume><elocation-id>116322</elocation-id><pub-id pub-id-type="doi">10.1016/j.jpba.2024.116322</pub-id><pub-id pub-id-type="pmid">38964167</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00200"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cafaro</surname><given-names>A.</given-names></name>
<name><surname>Conti</surname><given-names>M.</given-names></name>
<name><surname>Pigliasco</surname><given-names>F.</given-names></name>
<name><surname>Barco</surname><given-names>S.</given-names></name>
<name><surname>Bandettini</surname><given-names>R.</given-names></name>
<name><surname>Cangemi</surname><given-names>G.</given-names></name>
</person-group><article-title>Biological Fluid Microsampling for Therapeutic Drug Monitoring: A Narrative Review</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><elocation-id>1962</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines11071962</pub-id><pub-id pub-id-type="pmid">37509602</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00200"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Protti</surname><given-names>M.</given-names></name>
<name><surname>Mandrioli</surname><given-names>R.</given-names></name>
<name><surname>Mercolini</surname><given-names>L.</given-names></name>
</person-group><article-title>Tutorial: Volumetric absorptive microsampling (VAMS)</article-title><source>Anal. Chim. Acta</source><year>2019</year><volume>1046</volume><fpage>32</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2018.09.004</pub-id><pub-id pub-id-type="pmid">30482302</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00200"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kok</surname><given-names>M.G.M.</given-names></name>
<name><surname>Fillet</surname><given-names>M.</given-names></name>
</person-group><article-title>Volumetric absorptive microsampling: Current advances and applications</article-title><source>J. Pharm. Biomed. Anal.</source><year>2018</year><volume>147</volume><fpage>288</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2017.07.029</pub-id><pub-id pub-id-type="pmid">28803682</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00200"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giannoutsos</surname><given-names>S.</given-names></name>
<name><surname>Venkataramanan</surname><given-names>R.</given-names></name>
<name><surname>Dodeja</surname><given-names>P.</given-names></name>
<name><surname>Caritis</surname><given-names>S.</given-names></name>
</person-group><article-title>Applications of Volumetric Absorptive Microsampling Technique: A Systematic Critical Review</article-title><source>Ther. Drug Monit.</source><year>2023</year><volume>45</volume><fpage>431</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000001083</pub-id><pub-id pub-id-type="pmid">36917733</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00200"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jannetto</surname><given-names>P.J.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Effective Use of Mass Spectrometry in the Clinical Laboratory</article-title><source>Clin. Chem.</source><year>2016</year><volume>62</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2015.248146</pub-id><pub-id pub-id-type="pmid">26553795</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00200"><label>23.</label><element-citation publication-type="webpage"><article-title>ICH M10 on Bioanalytical Method Validation&#x02014;Scientific Guideline|European Medicines Agency n.d</article-title><comment>Available online: <ext-link xlink:href="https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline" ext-link-type="uri">https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-01">(accessed on 1 July 2024)</date-in-citation></element-citation></ref><ref id="B24-pharmaceutics-17-00200"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x02019;Urso</surname><given-names>A.</given-names></name>
<name><surname>Rudge</surname><given-names>J.</given-names></name>
<name><surname>Patsalos</surname><given-names>P.N.</given-names></name>
<name><surname>De Grazia</surname><given-names>U.</given-names></name>
</person-group><article-title>Volumetric Absorptive Microsampling: A New Sampling Tool for Therapeutic Drug Monitoring of Antiepileptic Drugs</article-title><source>Ther. Drug Monit.</source><year>2019</year><volume>41</volume><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000652</pub-id><pub-id pub-id-type="pmid">31095069</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00200"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vogeser</surname><given-names>M.</given-names></name>
<name><surname>Seger</surname><given-names>C.</given-names></name>
</person-group><article-title>A decade of HPLC-MS/MS in the routine clinical laboratory&#x02014;Goals for further developments</article-title><source>Clin. Biochem.</source><year>2008</year><volume>41</volume><fpage>649</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2008.02.017</pub-id><pub-id pub-id-type="pmid">18374660</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00200"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leung</surname><given-names>K.S.Y.</given-names></name>
<name><surname>Fong</surname><given-names>B.M.W.</given-names></name>
</person-group><article-title>LC-MS/MS in the routine clinical laboratory: Has its time come?</article-title><source>Anal. Bioanal. Chem.</source><year>2014</year><volume>406</volume><fpage>2289</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1007/s00216-013-7542-5</pub-id><pub-id pub-id-type="pmid">24337187</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00200"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vonk</surname><given-names>S.E.M.</given-names></name>
<name><surname>Altenburg</surname><given-names>J.</given-names></name>
<name><surname>Math&#x000f4;t</surname><given-names>R.A.A.</given-names></name>
<name><surname>Kemper</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor</article-title><source>J. Cyst. Fibros.</source><year>2024</year><volume>23</volume><fpage>1007</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2024.03.010</pub-id><pub-id pub-id-type="pmid">38494378</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="pharmaceutics-17-00200-t001"><object-id pub-id-type="pii">pharmaceutics-17-00200-t001_Table 1</object-id><label>Table 1</label><caption><p>Results of intra-day and inter-day accuracy and reproducibility assays for plasma, DPS and VAMS (n, replicates; (n) = 5). The quality control concentrations were, respectively, 0.020, 0.060, 0.400 and 10.000 &#x000b5;g/mL for LLOQ, QC low, QC medium and QC high. (SD, Standard deviation; CV%, coefficient of variation percentage).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="9" align="center" valign="middle" style="border-top:solid thin" rowspan="1">
<bold>IVACAFTOR</bold>
</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">
<bold>Plasma</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">
<bold>INTRA-DAY</bold>
</td><td colspan="4" align="center" valign="middle" rowspan="1">
<bold>INTER-DAY</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">2.48 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">11%</td><td align="center" valign="middle" rowspan="1" colspan="1">115%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.91 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">115%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" rowspan="1" colspan="1">2.74 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">91%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" rowspan="1" colspan="1">1.93 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">91%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.384</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 &#x000d7; 10<sup>&#x02212;2</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3%</td><td align="center" valign="middle" rowspan="1" colspan="1">96%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.372</td><td align="center" valign="middle" rowspan="1" colspan="1">3.08 &#x000d7; 10<sup>&#x02212;2</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">93%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">9.400</td><td align="center" valign="middle" rowspan="1" colspan="1">7.75 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">94%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.800</td><td align="center" valign="middle" rowspan="1" colspan="1">3.61 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">98%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">DPS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">INTRA-DAY</td><td colspan="4" align="center" valign="middle" rowspan="1">INTER-DAY</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">8.31 &#x000d7; 10<sup>&#x02212;4</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">115%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">114%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">3.79 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">108%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96 &#x000d7; 10<sup>&#x02212;3</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3%</td><td align="center" valign="middle" rowspan="1" colspan="1">109%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.436</td><td align="center" valign="middle" rowspan="1" colspan="1">2.28 &#x000d7; 10<sup>&#x02212;2</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">109%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.436</td><td align="center" valign="middle" rowspan="1" colspan="1">2.93 &#x000d7; 10<sup>&#x02212;2</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">109%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">9.600</td><td align="center" valign="middle" rowspan="1" colspan="1">3.87 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">96%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.400</td><td align="center" valign="middle" rowspan="1" colspan="1">7.28 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">94%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">VAMS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">INTRA-DAY</td><td colspan="4" align="center" valign="middle" rowspan="1">INTER-DAY</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">2.10 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">110%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">114%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">4.22 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">107%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" rowspan="1" colspan="1">6.18 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">99%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.420</td><td align="center" valign="middle" rowspan="1" colspan="1">4.50 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">11%</td><td align="center" valign="middle" rowspan="1" colspan="1">105%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.420</td><td align="center" valign="middle" rowspan="1" colspan="1">2.52 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">105%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">9.520</td><td align="center" valign="middle" rowspan="1" colspan="1">4.74 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">95%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.120</td><td align="center" valign="middle" rowspan="1" colspan="1">7.32 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">91%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">
<bold>TEZACAFTOR</bold>
</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">
<bold>Plasma</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">
<bold>INTRA-DAY</bold>
</td><td colspan="4" align="center" valign="middle" rowspan="1">
<bold>INTER-DAY</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">106%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">2.14 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">112%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">3.44 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">88%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td><td align="center" valign="middle" rowspan="1" colspan="1">1.57 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3%</td><td align="center" valign="middle" rowspan="1" colspan="1">87%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.364</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3%</td><td align="center" valign="middle" rowspan="1" colspan="1">91%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.364</td><td align="center" valign="middle" rowspan="1" colspan="1">2.47 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">91%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">10.520</td><td align="center" valign="middle" rowspan="1" colspan="1">7.83 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">105%</td><td align="center" valign="middle" rowspan="1" colspan="1">10.830</td><td align="center" valign="middle" rowspan="1" colspan="1">9.96 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" rowspan="1" colspan="1">108%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">DPS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">INTRA-DAY</td><td colspan="4" align="center" valign="middle" rowspan="1">INTER-DAY</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">1.66 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">110%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">2.92 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">13%</td><td align="center" valign="middle" rowspan="1" colspan="1">112%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">5.26 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">5.14 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">106%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.448</td><td align="center" valign="middle" rowspan="1" colspan="1">2.68 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">12%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.440</td><td align="center" valign="middle" rowspan="1" colspan="1">1.97 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">110%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">8.490</td><td align="center" valign="middle" rowspan="1" colspan="1">4.85 &#x000d7; 10<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">85%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.370</td><td align="center" valign="middle" rowspan="1" colspan="1">6.55 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">94%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">VAMS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">INTRA-DAY</td><td colspan="4" align="center" valign="middle" rowspan="1">INTER-DAY</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">15%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">115%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" rowspan="1" colspan="1">2.83 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.058</td><td align="center" valign="middle" rowspan="1" colspan="1">2.76 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">97%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.408</td><td align="center" valign="middle" rowspan="1" colspan="1">3.69 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1%</td><td align="center" valign="middle" rowspan="1" colspan="1">2%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.412</td><td align="center" valign="middle" rowspan="1" colspan="1">2.35 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">103%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">9.420</td><td align="center" valign="middle" rowspan="1" colspan="1">7.97 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.800</td><td align="center" valign="middle" rowspan="1" colspan="1">5.76 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">98%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">
<bold>ELEXACAFTOR</bold>
</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">
<bold>Plasma</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">
<bold>INTRA-DAY</bold>
</td><td colspan="4" align="center" valign="middle" rowspan="1">
<bold>INTER-DAY</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">105%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">2.30 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">110%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.058</td><td align="center" valign="middle" rowspan="1" colspan="1">4.80 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">98%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.057</td><td align="center" valign="middle" rowspan="1" colspan="1">2.87 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">95%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.404</td><td align="center" valign="middle" rowspan="1" colspan="1">2.15 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">101%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.384</td><td align="center" valign="middle" rowspan="1" colspan="1">3.25 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">96%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">9.910</td><td align="center" valign="middle" rowspan="1" colspan="1">6.13 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">99%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.950</td><td align="center" valign="middle" rowspan="1" colspan="1">4.66 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">DPS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">INTRA-DAY</td><td colspan="4" align="center" valign="middle" rowspan="1">INTER-DAY</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">13%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">112%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">2.83 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">2.72 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4%</td><td align="center" valign="middle" rowspan="1" colspan="1">108%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.480</td><td align="center" valign="middle" rowspan="1" colspan="1">2.62 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.432</td><td align="center" valign="middle" rowspan="1" colspan="1">2.04 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">108%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" rowspan="1" colspan="1">10.860</td><td align="center" valign="middle" rowspan="1" colspan="1">8.66 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">9.520</td><td align="center" valign="middle" rowspan="1" colspan="1">6.11 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" rowspan="1" colspan="1">95%</td></tr><tr><td colspan="9" align="center" valign="middle" rowspan="1">VAMS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="4" align="center" valign="middle" rowspan="1">INTRA-DAY</td><td colspan="4" align="center" valign="middle" rowspan="1">INTER-DAY</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td><td align="center" valign="middle" rowspan="1" colspan="1">Conc. mean (&#x000b5;g/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">CV%</td><td align="center" valign="middle" rowspan="1" colspan="1">Accuracy%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">4.90 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2%</td><td align="center" valign="middle" rowspan="1" colspan="1">15%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">5.21 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2%</td><td align="center" valign="middle" rowspan="1" colspan="1">115%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">3.19 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">5.78 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" rowspan="1" colspan="1">106%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.436</td><td align="center" valign="middle" rowspan="1" colspan="1">2.02 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5%</td><td align="center" valign="middle" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.420</td><td align="center" valign="middle" rowspan="1" colspan="1">3.28 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8%</td><td align="center" valign="middle" rowspan="1" colspan="1">105%</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.700</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.55 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.820</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.52 &#x000d7; 10<sup>&#x02212;1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98%</td></tr></tbody></table><table-wrap-foot><fn><p>CV%, percentage coefficient of variation; DPS, dried plasma spot; LLOQ, lower limit of quantification; QC, quality control; SD, Standard deviation; VAMS, Volumetric Absorptive Microsampling.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00200-t002"><object-id pub-id-type="pii">pharmaceutics-17-00200-t002_Table 2</object-id><label>Table 2</label><caption><p>Stability of IVA, TEZ and ELX measured on plasma, DPS and VAMS. Results are expressed as the accuracy and CV percentage (CV%) (CV% is the coefficient of variation percentage).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>IVACAFTOR</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>7 days</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>+4 &#x000b0;C</bold>
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>+25 &#x000b0;C (RT)</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103% (7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% (5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">3 days</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+4 &#x000b0;C</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+25 &#x000b0;C (RT)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93% (6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">TEZACAFTOR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">7 days</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+4 &#x000b0;C</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+25 &#x000b0;C (RT)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">3 days</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+4 &#x000b0;C</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+25 &#x000b0;C (RT)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93% (3%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106% (1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">ELEXACAFTOR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">7 days</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+4 &#x000b0;C</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+25 &#x000b0;C (RT)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% (3%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">3 days</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+4 &#x000b0;C</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">+25 &#x000b0;C (RT)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAMS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97% (5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QC high</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106% (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% (4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105% (3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% (4%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00200-t003"><object-id pub-id-type="pii">pharmaceutics-17-00200-t003_Table 3</object-id><label>Table 3</label><caption><p>Results of ETI concentrations (expressed in &#x000b5;g/mL) in plasma, VAMS and DPS. * Concentration value multiplied by the conversion factor.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="8" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>ELEXACAFTOR</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Patient</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Plasma concentration (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>DPS concentration (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>VAMS concentration measured (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>VAMS concentration corrected (</bold>
<bold>&#x000b5;g/mL) *</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>% difference plasma vs. DPS</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>% difference plasma vs. VAMS</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Blood-to-Plasma ratio (R)</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.559</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.666</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.509</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.248</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.479</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.961</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.343</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.387</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.462</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.099</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;11%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.897</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.947</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.698</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.968</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.477</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.161</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.973</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.518</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.654</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.965</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.052</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.545</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.572</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.535</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.677</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.208</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;18%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>TEZACAFTOR</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Patient</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Plasma concentration (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>DPS concentration (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>VAMS concentration measured (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>VAMS concentration corrected (</bold>
<bold>&#x000b5;g/mL) *</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>% difference plasma vs. DPS</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>% difference plasma vs. VAMS</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Blood-to-Plasma ratio (R)</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.919</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.100</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.688</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.621</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.483</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.403</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.267</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.895</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.721</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.124</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.159</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.148</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.601</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.050</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.599</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.435</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.846</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.508</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;11%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.631</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.481</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.801</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.847</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.163</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.040</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.736</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.235</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>IVACAFTOR</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Patient</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Plasma concentration (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>DPS concentration (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>VAMS concentration measured (</bold>
<bold>&#x000b5;g/mL)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>VAMS concentration corrected (</bold>
<bold>&#x000b5;g/mL) *</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>% difference plasma vs. DPS</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>% difference plasma vs. VAMS</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Blood-to-Plasma ratio (R)</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.757</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.804</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.758</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.793</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.552</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.616</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.999</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.883</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.507</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.919</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.357</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.384</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.201</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.351</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.130</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.127</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.072</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.128</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.234</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.179</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.860</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.356</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.441</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.436</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.317</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.498</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;20%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72</td></tr></tbody></table></table-wrap></floats-group></article>